Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
262
¥ million (year-on-year change in operating loss)Wording
Conditional
How definitive the wording is.Results for this period
Full year2024年4月1日〜2025年3月31日Non-consolidated (standalone)Japanese GAAPNet Sales7,789¥ millionYear on year +0.7%Progress 77.9%
Operating profit-457¥ million
Ordinary income-409¥ million
Net income attributable to owners of the parent64¥ millionYear on year -40.9%Progress 32.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share1円85銭
Operating Margin△5.9％
Financial position at period-end
Total assets15,002¥ million
of which net assets 11,610 ¥ millionEquity ratio 77.4%vs. prior year-end -0.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-592
Investment-13
Financials-103
Net change-708
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥2,954 million
Segment revenue
Pharmaceuticals3,473,14844.6%+2.4%
Healthcare Business2,345,10530.1%-4.4%
Global Business1,788,61423.0%+4.1%
Real estate leasing182,5922.3%+4.8%
Segment profit
Pharmaceuticals-1,086,117
Healthcare Business331,730
Global Business237,960
Real estate leasing58,629
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,000 million (YoY +28.4%)
Operating profit¥200 million
Ordinary income¥250 million
Net income¥200 million (YoY +210.4%)
Annual Dividend Forecast¥3 per share → ¥3 per share（0.0%）
Payout ratioFiscal year ending March 2025 162 ％ / 2026年3月期（予想） 52.1 ％
Shareholder Return PolicyThe basic policy is to maintain a dividend payout ratio of 50% or higher
Factors Behind Changes in Business Performance
既存後発医薬品や国内用乳酸菌原料等の増加で売上高は増加した一方、医療機器販売に向けた費用や人件費等の増加で販管費が増加した。投資有価証券売却益を計上した。
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsNo applicable matters.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥419,945 thousand / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand
Depreciation and amortization¥430,343 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable Available / Subject person Not disclosed
Issued Shares at Period-End34,838,325
Treasury Shares at Period-End132,052
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2024年4月1日〜2025年3月31日 |
| Net Sales | ¥7,789 million (YoY +0.7%) |
| Operating profit | ¥-457 million |
| Ordinary income | ¥-409 million |
| Profit attributable to owners of the parent | ¥64 million (YoY -40.9%) |
| Net income per share | 1円85銭 |
| Operating Margin | △5.9％ |
| Equity ratio | End of the current fiscal period 77.4 / End of previous period 78 |
| Total assets | ¥15,002 million |
| Net assets | ¥11,610 million |
| Cash flows from operating activities | ¥-592 million |
| Cash flows from investing activities | ¥-13 million |
| Cash flows from financing activities | ¥-103 million |
| Cash and cash equivalents at end of period | ¥2,954 million |
| Full-year earnings forecast | Net Sales ¥10,000 million (YoY +28.4%) / Operating profit ¥200 million / Ordinary income ¥250 million / Net income ¥200 million (YoY +210.4%) |
| Annual Dividend Forecast | ¥3 per share → ¥3 per share（0.0%） |
| Payout ratio | Fiscal year ending March 2025 162 ％ / 2026年3月期（予想） 52.1 ％ |
| Shareholder Return Policy | The basic policy is to maintain a dividend payout ratio of 50% or higher |
| Segment revenue | Pharmaceuticals ¥3,473,148 thousand (YoY +2.4%) / Healthcare Business ¥2,345,105 thousand (YoY -4.4%) / Global Business ¥1,788,614 thousand (YoY +4.1%) / Real estate leasing ¥182,592 thousand (YoY +4.8%) |
| Segment profit | Pharmaceuticals ¥-1,086,117 thousand / Healthcare Business ¥331,730 thousand / Global Business ¥237,960 thousand / Real estate leasing ¥58,629 thousand |
| Depreciation and amortization | ¥430,343 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥419,945 thousand / Extraordinary loss Loss on disposal of non-current assets ¥1,936 thousand, Office relocation expenses ¥1,314 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Available / Subject person Not disclosed |
| Issued Shares at Period-End | 34,838,325 |
| Treasury Shares at Period-End | 132,052 |
| Factors Behind Changes in Business Performance | 既存後発医薬品や国内用乳酸菌原料等の増加で売上高は増加した一方、医療機器販売に向けた費用や人件費等の増加で販管費が増加した。投資有価証券売却益を計上した。 |
Items this document does not state (4)
Revision to Earnings ForecastRegional salesOrders received and order backlogChanges in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.既存後発医薬品や国内用乳酸菌原料などの増加で売上高は増加したが、医療機器販売に向けた費用や人件費などの増加により販売費及び一般管理費が増加した。投資有価証券売却益419百万円の計上により当期純利益は黒字となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.